Compare Ferrari NV (RACE) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Travere Therapeutics Inc. Common Stock — how do they compare? Ferrari NV trades at $396.44 (market cap $68.43B), while Travere Therapeutics Inc. Common Stock trades at $54.94 (market cap $5.02B). The key difference: Ferrari NV is far larger — about 13.6× Travere Therapeutics Inc. Common Stock's market cap, and Ferrari NV pays a 1.09% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ferrari NV for 126 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RACE | TVTX | |
|---|---|---|
Market Cap | $68.43B | $5.02B |
Volume | 343,086 | 2,060,842 |
Sector | Consumer Cyclical | Health |
52-Week High | $436.54 | $67.52 |
52-Week Low | $314.63 | $26.79 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | $70.30B | $5.15B |
Dividend Yield | 1.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $395.23, up 0.93% with strong fundamentals including 22.25% net margins and 45.45% ROE. The stock shows consistent earnings beats with Q2 2026 EPS of $2.99 exceeding expectations. Technical indicators signal bearish momentum near key resistance at $395, while analyst consensus remains strongly bullish with a $462.75 price target. Recent news highlights institutional accumulation and a €250 million share buyback program.
Outlook remains positive given premium brand positioning and operational efficiency, though high valuation multiples (P/E 37.41) and technical resistance pose near-term risks. The combination of shareholder returns via buybacks and sustained profitability supports long-term growth potential despite macroeconomic sensitivity.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
